Skip to main content

mat2a inhibitor ide397

Generic: MAT2A Inhibitor IDE397

mat2a inhibitor ide397: sourced relationships with 1 company · 3 clinical trials tracked.

mat2a inhibitor ide397 evidence translation

What we can confirm

What it means

Source-backed records connect mat2a inhibitor ide397 to IDYA; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could mat2a inhibitor ide397 → IDYA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 1 study sponsors

Related indications

NSCLC Adenocarcinoma; Solid TumorBladder CancerMesotheliomaPancreatic CancerSolid Tumor
Dated Pipeline Records (1)
CompanyDated record stage
IDEAYA Biosciences, Inc. (IDYA)
developer · Reported 2026-02-17 · Current development: unknownSource
NSCLC Adenocarcinoma; Solid Tumor
Phase 1
Clinical Trial Registry Records (3)

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

NCT07277413Registry updated 2026-09-28·Phase 1·IDYA
Recruiting

Primary endpoint: Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)

Interventionalopen260 targetStarted 2026-03Completion 2028-0423 sites · United StatesIDEAYA Biosciences

A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors

NCT05975073Registry updated 2026-04-22·Phase 1/Phase 2·AMGN
Completed

Primary endpoint: Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)

Interventionalopen53 enrolledStarted 2023-08Completion 2026-0327 sites · Australia, Canada, Denmark, South Korea…Amgen

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

NCT04794699Registry updated 2026-04-09·Phase 1·IDYA
Active, not recruiting

Primary endpoint: Dose-limiting Toxicities (DLTs) of IDE397

Interventionalopen169 enrolledStarted 2021-04Completion 2027-0237 sites · Australia, France, Germany, South Korea…IDEAYA Biosciences

Frequently asked questions

Which companies have sourced relationships with mat2a inhibitor ide397?

mat2a inhibitor ide397 has dated SEC/FDA relationship records for IDEAYA Biosciences, Inc..

How many clinical trials involve mat2a inhibitor ide397?

BioSniper tracks 3 clinical trials involving mat2a inhibitor ide397.